Four products, one page, and very little else on it
The listing gives an injectable semaglutide, an oral semaglutide, an injectable tirzepatide and an oral tirzepatide, each with a one-line description and an as-low-as figure. The two semaglutide products share a figure and the two tirzepatide products share a higher one.
We measured the page rather than describing it: the extracted visible text runs to two thousand four hundred and sixty-eight characters in total. That is the census behind everything this review says is absent. There is no plan length anywhere, no dose, no membership statement, no state list and no clinician.
Every figure carries an asterisk. Nothing on the page resolves it.
The oral costs the same as the injection
Twenty-seven of the one hundred and fifty-eight sellers here price an oral route at all, and most price it above the injection. This seller prices them identically, for both molecules.
That is the one genuinely informative thing on the page, and it is the reason to keep this row: it is a data point about what a needle-free route costs when a seller is not treating it as a premium product.
The terms page belongs to another brand
The terms and conditions document carries a page title naming a different brand, while its body names this seller's own operating company in its opening section. That is the signature of a template that was filled in halfway.
It is not, on its own, evidence about how the business runs. It is evidence about how much attention was paid to the document a buyer is agreeing to, and it belongs beside the four unexplained asterisks rather than apart from them.
No compounding pharmacy is named and no individual clinician is named. No service area is published. The membership question is not answered.
Luci's published pricing
| Medication | Price | Verified |
|---|---|---|
| Semaglutide (compounded) | $99/moas low as, per month, with an asterisk the product listing does not resolve on the page | September 2026source |
| Semaglutide (compounded-oral) | $99/moas low as, per month; the seller prices its oral semaglutide identically to its injectable one | September 2026source |
| Tirzepatide (compounded) | $145/moas low as, per month, with an asterisk the product listing does not resolve on the page | September 2026source |
| Tirzepatide (compounded-oral) | $145/moas low as, per month; the seller prices its oral tirzepatide identically to its injectable one | September 2026source |
compareglp may earn a commission when a reader signs up with a provider through a link on this site. 4 of the 158 providers reviewed here are paid partners today; the other 154 are not. See how this works.
See Luci's current price →Good fit if
- Readers comparing an oral and an injectable price from a seller that charges the same for both.
- Buyers who want a plain catalogue with a figure on every item and nothing else to read.
Look elsewhere if
- Anyone who needs a plan length, a dose, a state list or a membership answer. None of them is on the page.
- Readers who want the terms document they are agreeing to to be titled after the company they are buying from.
- Buyers who want the compounding pharmacy or a clinician named.
How this review was verified
- Re-read the product listing and the terms and conditions on 6 September 2026, comparing the requested path to the effective path and running a nonsense path against the host in the same run.
- Measured the product page's extracted visible text and recorded the character count, so that every statement here about something being absent has a census attached rather than an impression.
- Recorded the terms page title as read, rather than paraphrasing it.
- Screened the operating entity and the brand name against FDA's live warning-letter record with a known letter as a positive control and a nonsense string as a negative control in the same pass. The brand name alone returns unrelated results and none names this company. Untitled letters are published separately and were not searched.